课题基金 / 基金详情

ROSWELL PARK MOUSE MOLECULAR GENETICS PROGRAM FACILITIES

ROSWELL PARK MOUSE MOLECULAR GENETICS PROGRAM FACILITIES
罗斯威尔公园小鼠分子遗传学项目设施
批准号:
2722177
负责人:
YOUCEF B RUSTUM
金额:
$74.7万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-09-15 至 2000-09-14

项目摘要

项目成果

YOUCEF B RUSTUM的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Roswell Park Cancer Institute (RPCI), an NCI-designated comprehensive cancer center, is in the midst of a Major Modernization Program, by which the year 2002 will replace and/or renovate nearly all of the buildings on its 25-acre campus. A new Medial Research Complex Building (MRC) including a centralized Vivarium, was completed in December 1997. Since the early phases of major modernization, a portion of the MRC, including biosafety level 2/3 laboratories, has been planned as shell space. However, as the project has progressed, events beyond the Institute's control including the imposition of a project labor agreement, and the engineer's $15 million underestimate on the reconstruction of the Institute's power plant have resulted in an increase the amount of shell space in the MRC. An NIH construction grant and RPCI matching funds will be used to fit-up 10, 164 net square feet of shell space in the MRC including a glasswasher and two cold rooms for the Mouse Molecular Genetics Program. The five investigators compromising this Program (Drs. Elliot, Gross, Held, Manly, and Swank) have extramural grants totaling $1, 414, 774 in direct costs in the current year (current support from NIH is $1, 365, 873). Climate-controlled connections will link the MRC with the adjacent Vivarium, and new hospital, scheduled for completion in 1998. Construction of new facilities will synergize ongoing efforts in mouse molecular genetics and the identification of key genes involved in cancer and human disease through animal modeling and other developing technologies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Irinotecan in Combination with Celecoxib
ROSWELL PARK DNA REPLICATION PROGRAM FACILITIES
THYMIDYLATE SYNTHASE INHIBITORS IN HEAD AND NECK CANCER